Clinical Trial Update: Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for BOS161721 in systemic lupus erythematosus completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• BOS161721

Snippet

Sponsor: Boston Pharmaceuticals | Conditions: Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-14